CD93 and chronic myelogenous leukemia, BCR-ABL1 positive: Notwithstanding, MFC-MRD diagnostics may be useful to identify and track the CML-LSC population (immunophenotypically identified by the co-expression of CD34, CD26, CD56, CD93, CD123, and lack of CD38), whose eradication represents the ultimate challenge in CML treatment [26,27,28,29].